Managing Partner
Aaron McKeon-Fish has over 15 years of experience within biotechnology and life science industry, serving as a thought partner and support strategy development for life sciences organizations across a breadth of therapeutic areas, including oncology, immunology, neurology, cardiology & rare disease. Areas of expertise include pricing & contracting, channel economics, launch excellence playbooks, loss of exclusivity/biosimilar channel targeting & positioning. His deep expertise in competitive scenario planning has supported many clients’ GTM strategies aligned to optimizing patient access.
Aaron holds a B.S. in biochemistry from The College of New Jersey, and an M.B.A (strategy, management) from New York University Stern School of Business. Prior to joining TDG, Aaron worked in life sciences strategy consulting at McCann Health and in early stage oncology/ hematology drug discovery at The Children’s Hospital of Philadelphia.
Managing Partner
Sophia Tan has over 15 years of experience in the biotechnology and life sciences industry, specialized in market access and commercial strategy with in-depth expertise in clinical pathways, value-based care, and precision medicine. She has been a thought partner for numerous biopharma clients, providing strategic advice on a wide array of issues including clinical pathway strategy and operational planning, payer and provider channel engagement, go-to-market strategy, and value-based care.
Prior to joining TDG, Sophia received her doctoral degree and led clinical research on neural stem cells at Weill Cornell and Memorial Sloan-Kettering. Her research has been presented at international conferences and published in top peer-reviewed journals.
Managing Partner
Jen Klarer has over a decade of experience in multi-channel market analysis and strategic access optimization, spanning specialty therapeutic categories including cell and gene therapy, oncology, immunology, and rare disease. Areas of differentiated expertise include coverage and reimbursement modeling, provider site activation planning and commercial operations configuration (distribution, patient services, and field team execution) to optimize patient reach.
Jen has a Bachelor of Arts in chemistry from Franklin & Marshall College and a Master of Science in biomedical engineering from Columbia University. Prior to joining TDG, she conducted six years of academic research, including pre-clinical study of an autologous cell therapy for critical limb ischemia.
Managing Partner
James Pisano has extensive experience across specialty therapeutic classes including immunology, neuroscience, ultra-rare disease, and women’s health. Areas of particular focus include economic modeling, deconstructing evolution in stakeholder business models, and mapping influence across customers.
James studied biomedical engineering & economics, earning a bachelor’s degree from Northwestern University. During his time at Northwestern, he conducted research on the physiological implications of ischemic stroke.
Managing Partner
Matthew Cunningham has broad experience in oncology provider model evolution, precision medicine & population health strategies. Matt has supported provider channel engagement strategies for dozens of oncology brands and continues to work with many clients in the development of key account / field team infrastructure and targeting strategies.
Matt studied healthcare management & policy, earning his bachelor’s degree from Georgetown University, and has administrative experience at both an NCI-accredited cancer center and a community oncology practice.
Partner
Sachin Purwar brings over 20 years of biopharma and life sciences commercialization experience to The Dedham Group, with a focus on commercial and portfolio strategy, launch excellence, opportunity assessments, forecasting, and corporate development. He supports organizations across several therapeutic areas, including oncology, neurology, rare diseases, immunology, and women’s health.
Prior to joining TDG, he was a managing director at Trinity Life Sciences and Syneos Health Consulting. Sachin also held positions at Kraft Foods, Blott Asset Management, and Pfizer, where he was a specialty sales representative serving the urology, cardiovascular, endocrine, OB/GYN, and respiratory markets.
Sachin holds an MBA from Columbia Business School and a BS in biochemistry and molecular biology from The Pennsylvania State University.
Partner
Hannah Baxter has extensive experience in cross-channel market access strategy development and optimization, with expertise spanning oncology, neurology, and rare diseases. She specializes in payer models & vertical integration, provider access strategies, channel economics, and precision medicine strategies, helping organizations navigate complex healthcare & therapeutic landscapes to drive value and improve patient access & outcomes.
Hannah holds a B.A. in organizational sciences, with a minor in biology, from The George Washington University, and has prior analytical experience in biotechnology and large pharmaceutical organizations.
Partner
Olivia D'Alleva has nearly a decade of experience in market access strategy consulting, partnering with leading pharmaceutical and biotechnology organizations across immunology, rare disease, and other specialty therapeutics. She serves as a trusted advisor to top 10 pharmaceutical companies and emerging biotech organizations, supporting commercial strategy development from pre-launch through lifecycle management. Areas of expertise include payer and provider access strategy, channel economics, patient support services, and pricing and contracting considerations. Her experience developing innovative market access solutions for complex autoimmune and ultra-orphan therapies has helped clients optimize patient access while navigating evolving access landscapes.
Olivia holds a Bachelor of Arts in Biology from the College of the Holy Cross, where she also completed the Health Professions Advising Program and Pre-Business Program. Prior to joining The Dedham Group, she held positions in hospital administration and led the healthcare practice at a leading knowledge search firm.
Partner
Daniel Colacurcio has extensive experience in the life sciences strategy space, with a primary focus in oncology market access. Daniel has been a strategic partner across numerous large pharma and biotech clients in navigating the evolving oncology space. Areas of strategic focus include clinical pathways & care standardization tools, engagement strategies for provider & payer stakeholders, and specialized areas such as urologic oncology.
Daniel holds a PhD in neuroscience from The University of Pennsylvania, and a BA in cellular & molecular neuroscience from The Johns Hopkins University. Prior to joining TDG in 2018, Daniel conducted research in Alzheimer's Disease as a postdoctoral fellow at The Nathan Kline Institute for Psychiatric Research.
Partner
Katie Moses has extensive experience in commercialization and lifecycle management for specialty and complex therapeutics across categories including cell therapy, gene therapy, oncology, rare disease, immunology, and neurology. Areas of expertise include coverage analytics, reimbursement modeling, operational workflow mapping, patient capture opportunity testing, and provider site activation strategy.
Katie has Bachelor of Science in Chemical Engineering, with a minor in Business Administration, from the University of Michigan
VP, Business Operations
As Dedham’s VP, Business Operations, Dave Sauchelli is responsible for overseeing the firm’s finance and business operations functions, including FP&A, human resources, contracting, and systems integrations/implementations.
Dave joined Dedham in 2013 and works to develop strategic business and accelerated growth plans alongside the partners.
With over 15 years of professional experience, he began his career at Prudential Financial helping individuals and institutions improve their financial wellness. Dave studied finance, earning his bachelor’s degree from New Jersey City University.